The Cardiovascular Drugs market research survey offers an inclusive evaluation of the market and includes crucial future predictions, industry documentation and market reality. This report reveals a comprehensive study of the collected information, with key players, sellers, and market dealers, along with key aspects influencing the market. The Cardiovascular Drugs Market research study examines the international and regional breakdown of the industry and its uniqueness, market shares, trends, outlines, industry classifications, and the constantly transforming global market ecosystem. The Cardiovascular Drugs market research report provides profits predictions and geographic regions of the organization. The study's purposes are to present the product development in North America, China, Europe, South East Asia, Japan, and the rest of the world.

Market Overview

The Cardiovascular Drugs market size was estimated at USD 168.36 billion in 2023 and is projected to reach USD 221.85 billion in 2030 at a CAGR of 4.02% during the forecast period 2023-2030.

Get a Sample Copy of the Report: https://www.delvens.com/get-free-sample/cardiovascular-drugs-market-trends-forecast-till-2030

Cardiovascular drugs are medications that are used to treat various conditions related to the heart and blood vessels. They are prescribed to manage heart diseases and other cardiovascular disorders. Cardiovascular medicines are often used in combination to treat different aspects of a cardiovascular disease. There are various types of cardiovascular drugs such as antihypertensives that are used to lower blood pressure, anticoagulants that are used to prevent blood clots, antihyperlipidemic that are used to lower cholesterol and triglyceride levels, antiarrhythmics that are used to regulate abnormal heart rhythms. Most cardiovascular drugs are prescribed to treat hypertension and dyslipidaemia which are majorly responsible for the formation of atherosclerotic plaque within blood vessels restricting blood flow to the body parts resulting in multiple cardiac indications such as stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis.

The cardiovascular drugs market can be segmented based on drug class into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. Based on indication the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. Based on distribution channel, the market can be segmented into hospital, pharmacies and others. Lastly, based on region the market is bifurcated into North America, Europe, Asia-Pacific, Middle East and Africa and South America. Rising prevalence of cardiovascular diseases (CVDs) globally, growing research and development and investment in efficient drug development and increasing availability of reimbursement policies are the factors that are contributing to the growth of the market during the forecast period. Moreover, the increasing number of admissions in hospitals, as well as critical care units owing to cardiovascular diseases (CVDs) has created demand for the development of cardiovascular drugs for treatment.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cardiovascular diseases to significant risks. However, the demand for cardiovascular drugs increased during the pandemic owing to the increased risk of infection among patients with cardiovascular diseases (CVDs).

Key Findings

·         Based on drug class the market can be segmented into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. The anti-hypertensives dominated the market in this segment and is expected to continue to dominated the market during the forecast period, due to the high prevalence of stress, anxiety and hypertension among people.

·         Based on indication, the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. The hypertension segment dominated the market in this segment and garnered the highest share. It is expected to dominate the cardiovascular drugs market during the forecast period due to increased target population suffering from hypertension, and increasing product approvals.

·         On the basis of distribution channel, the market can be segmented into hospitals, pharmacies and others. The hospitals segment dominated the market in this segment which can be attributed to the high demand for cardiovascular drugs in the hospital.

·         The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. This can be attributed to several factors such as sedentary lifestyle of people in the region, improper diet, stress and anxiety. Moreover, increasing level of product launches, approvals and clinical trials is driving the growth of the market.

Regional Analysis

North America to Dominate the Market

·         North America is estimated to account for the largest market share during the forecast period. Lack of physical activity leading to a sedentary lifestyle, improper diet, stress and anxiety are resulting in chronic diseases such as diabetes and obesity leading to rising in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.

·         In addition to that, product launches, approvals, and clinical trials are increasing in the region which is expected to drive the growth of the market during the forecast period.

Competitive Landscape

·         Amgen Inc

·         Baxter

·         Bayer AG

·         Boehringer Ingelheim International GmbH

·         F. Hoffmann-La Roche Ltd

·         Gilead Sciences Inc

·         Johnson & Johnson

·         Lupin

·         Merck & Co., Inc. (MSD)

·         Novartis AG

·         Pfizer Inc.

·         Sanofi S A

·         Bristol-Myers Squibb Company

·         AstraZeneca

·         Janssen Pharmaceuticals, Inc.

·         Daiichi Sankyo

·         Portola Pharmaceuticals

·         United Therapeutics Corp

Recent Developments

·         In May 2022, Amgen revealed positive data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events.

·         In February 2022, the Food and Drug Administration (FDA) expanded its approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization. The medication was approved in August 2021 to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction (HFrEF).

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/cardiovascular-drugs-market-trends-forecast-till-2030

Reasons to Acquire

·         Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.

·         Gain authentic and granular data access for the Cardiovascular Drugs Market to understand the trends and the factors involved in changing market situations.

·         Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.

·         In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Table of Contents

The Cardiovascular Drugs Market is segmented into various segments such as drug class, indication, distribution channel and region:

Based on Drug Class

·         Anti-hyperlipidaemic

·         Anti-hypertensives

·         Anti-coagulants

·         Anti-arrhythmic

Based on the Indication

·         Hypertension

·         Hyperlipidaemia

·         Coronary Artery Disease

·         Arrhythmia

Based on the Distribution Channel

·         Hospital

·         Pharmacies

Based on Region

Asia Pacific

·         Japan

·         China

·         India

·         Australia

·         South Korea

·         Vietnam

·         New Zealand

·         Philippines

·         Thailand

·         Malaysia

·         Hong Kong

·         Taiwan

·         Singapore

·         Indonesia

·         Sri Lanka

·         Rest of Asia-Pacific

North America

·         U.S.

·         Canada

·         Mexico

Europe

·         Germany

·         U.K.

·         France

·         Italy

·         Spain

·         Sweden

·         Austria

·         Finland

·         Belgium

·         Turkey

·         Russia

·         Poland

·         Hungary

·         Czech Republic

·         Switzerland

·         Netherlands

·         Rest of Europe

South America

·         Brazil

·         Argentina

·         Chile

·         Colombia

·         Rest of South America

·         Middle East & Africa

South Africa

·         U.A.E.

·         Saudi Arabia

·         Oman

·         Qatar

·         Iran

·         Egypt

·         Rest of Middle East and Africa

Get Direct Order of this Report: https://www.delvens.com/checkout/cardiovascular-drugs-market-trends-forecast-till-2030

Browse Related Reports:

Cardiovascular Drugs Market – Trends Forecast Till 2030

Human Insulin Market – Trends forecast Till 2030

Pharmaceutical Quality Control Market – Trends Forecast Till 2030

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports, and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on the country, regional, and global business environment. We have a database for more than 45 industries globally in more than 115+ major countries.

Delvens database assists clients by providing in-depth information on crucial business decisions. Delvens offers significant facts and figures across various industries: Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, and Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM